BNP Paribas Financial Markets Makes New Investment in Can-Fite BioPharma Ltd. (NYSE:CANF)

BNP Paribas Financial Markets bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 25,185 shares of the company’s stock, valued at approximately $41,000.

Separately, Rhumbline Advisers raised its holdings in Can-Fite BioPharma by 58.6% in the fourth quarter. Rhumbline Advisers now owns 26,880 shares of the company’s stock worth $44,000 after purchasing an additional 9,935 shares in the last quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Stock Up 0.5%

CANF opened at $1.10 on Wednesday. Can-Fite BioPharma Ltd. has a 52-week low of $0.98 and a 52-week high of $4.69. The company has a market cap of $3.89 million, a P/E ratio of -0.61 and a beta of 1.18. The firm’s 50-day moving average price is $1.20 and its 200-day moving average price is $1.49.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, April 15th. Wall Street Zen initiated coverage on shares of Can-Fite BioPharma in a report on Thursday, April 24th. They set a “sell” rating on the stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.